Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Revenue (2020 - 2023)

Inhibikase Therapeutics (IKT) has disclosed Revenue for 4 consecutive years, with $1.0 as the latest value for Q4 2023.

  • On a quarterly basis, Revenue fell 100.0% to $1.0 in Q4 2023 year-over-year; TTM through Sep 2024 was $1.0, a 100.0% decrease, with the full-year FY2023 number at $260501.0, up 111.03% from a year prior.
  • Revenue was $1.0 for Q4 2023 at Inhibikase Therapeutics, down from $79569.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $1.4 million in Q1 2021 to a low of $1.0 in Q4 2023.
  • A 4-year average of $261438.4 and a median of $72045.0 in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: soared 3169.86% in 2022, then tumbled 100.0% in 2023.
  • Inhibikase Therapeutics' Revenue stood at $170416.0 in 2020, then crashed by 98.86% to $1944.0 in 2021, then skyrocketed by 3169.86% to $63566.0 in 2022, then crashed by 100.0% to $1.0 in 2023.
  • Per Business Quant, the three most recent readings for IKT's Revenue are $1.0 (Q4 2023), $79569.0 (Q3 2023), and $116410.0 (Q2 2023).